Jonathan Appleby

Jonathan Appleby is currently the Chief Scientific Officer at Mogrify Limited, where they focus on advancing innovative therapeutic programs, particularly in otology, ophthalmology, and diabetes. Previously, they served as Chief Scientific Officer at the Cell and Gene Therapy Catapult from 2018 to 2024, promoting the growth of the cell and gene therapy industry. Appleby led significant projects at GSK as CSO for Cell and Gene Therapy in Rare Diseases from 2010 to 2018, including the development of Strimvelis, the first licensed stem cell gene therapy. They earned a degree in Molecular Genetics from the University of Leeds, where they studied from 1989 to 1995.